2009
Fibrosis of the Hand Secondary to Jet Propellant Exposure: A New Clinical Syndrome
Spock CR, Masood Q, Cowper SE, Narayan D. Fibrosis of the Hand Secondary to Jet Propellant Exposure: A New Clinical Syndrome. Plastic & Reconstructive Surgery 2009, 124: 266e-267e. PMID: 20009810, DOI: 10.1097/prs.0b013e3181b98e91.Peer-Reviewed Case Reports and Technical Notes
2008
Gadolinium – is it to blame?
Cowper SE. Gadolinium – is it to blame? Journal Of Cutaneous Pathology 2008, 35: 520-522. PMID: 18399814, DOI: 10.1111/j.1600-0560.2008.01027.x.Commentaries, Editorials and LettersClinical and histological findings in nephrogenic systemic fibrosis
Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. European Journal Of Radiology 2008, 66: 191-199. PMID: 18325705, DOI: 10.1016/j.ejrad.2008.01.016.Peer-Reviewed Original ResearchNSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment
Knopp EA, Cowper SE. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment. Seminars In Dialysis 2008, 21: 123-128. PMID: 18226008, DOI: 10.1111/j.1525-139x.2007.00399.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisGadolinium-containing contrast agentsEarly recognitionSystemic fibrosisAcute kidney diseaseSignificant risk factorsInvolved extremityRenal dysfunctionRenal insufficiencyExtracorporeal photopheresisRenal functionMedical therapyMuscle weaknessKidney diseaseRisk factorsDistressing diseaseEarly treatmentPhysical therapyEffective treatmentEarly symptomsEarly signsPatientsBeneficial effectsFibrosisTherapyNephrogenic Systemic Fibrosis: An Overview
Cowper SE. Nephrogenic Systemic Fibrosis: An Overview. Journal Of The American College Of Radiology 2008, 5: 23-28. PMID: 18180005, DOI: 10.1016/j.jacr.2007.08.013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2007
Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders
Cowper SE, Kuo PH, Bucala R. Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders. Arthritis & Rheumatism 2007, 56: 3173-3175. PMID: 17907160, DOI: 10.1002/art.22926.Commentaries, Editorials and LettersNephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor
Moreno‐Romero J, Segura S, Mascaró JM, Cowper SE, Julià M, Poch E, Botey A, Herrero C. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. British Journal Of Dermatology 2007, 157: 783-787. PMID: 17627792, DOI: 10.1111/j.1365-2133.2007.08067.x.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisDevelopment of NSFRenal insufficiency patientsOnset of symptomsNephrogenic fibrosing dermopathyPossible aetiological factorsMagnetic resonance angiographyRenal diseaseCase seriesAetiological factorsSystemic fibrosisResonance angiographyFibrotic conditionsPatientsParamagnetic contrast agentHistory of useDiseaseContrast agentsAngiographyFibrosisDermopathyEtiologyGadoliniumSymptomsGadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis
High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. Journal Of The American Academy Of Dermatology 2007, 56: 710-712. PMID: 17289213, DOI: 10.1016/j.jaad.2007.01.022.Peer-Reviewed Original ResearchNephrogenic Systemic Fibrosis: A Population Study Examining the Relationship of Disease Development to Gadolinium Exposure
Deo A, Fogel M, Cowper SE. Nephrogenic Systemic Fibrosis: A Population Study Examining the Relationship of Disease Development to Gadolinium Exposure. Clinical Journal Of The American Society Of Nephrology 2007, 2: 264-267. PMID: 17699423, DOI: 10.2215/cjn.03921106.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisGadolinium-containing contrast agentsGadolinium exposureIncidence of NSFSevere renal failurePopulation of patientsMajor risk factorOccurrence of NSFDevastating complicationESRD populationRenal failureSignificant morbidityRadiologic studiesRisk factorsSystemic fibrosisPopulation studiesESRDPatientsDisease developmentRecent reportsExposureContrast agentsRiskMorbidityComplicationsGadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1
Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1. Radiology 2007, 242: 647-9. PMID: 17213364, DOI: 10.1148/radiol.2423061640.Commentaries, Editorials and LettersNephrogenic Systemic Fibrosis: A Review and Exploration of the Role of Gadolinium
Cowper SE. Nephrogenic Systemic Fibrosis: A Review and Exploration of the Role of Gadolinium. Advances In Dermatology 2007, 23: 131-154. PMID: 18159899, DOI: 10.1016/j.yadr.2007.07.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2006
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis
High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. Journal Of The American Academy Of Dermatology 2006, 56: 21-26. PMID: 17097388, DOI: 10.1016/j.jaad.2006.10.047.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisNSF patientsSystemic fibrosisGadolinium-containing contrast materialSubset of patientsSoft tissueNumber of patientsPilot investigationTissues of patientsGadolinium-based contrastGadolinium-containing contrast agentsParaffin-embedded specimenNegative controlRenal insufficiencyDevelopment of diseasePathophysiologic mechanismsUnknown etiologyEpidemiologic associationPatientsContrast materialTissue residence timeSingle histological sectionTissue specimensBlocks of tissueDetection of gadoliniumNephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)
Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Current Opinion In Rheumatology 2006, 18: 614-617. PMID: 17053507, DOI: 10.1097/01.bor.0000245725.94887.8d.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisSystemic fibrosisNephrogenic fibrosing dermopathyRenal insufficiencyClinical awarenessSystemic diseaseClinical spectrumTreatment optionsFibrogenic factorsEffective therapyFatal disorderEnigmatic disorderClinical reportsCardinal featuresFibrosisSpecific causesDisordersPathogenesisFibrocytesFuture studiesCauseRheumatologistsPatientsEtiopathogenesisRegistryEditorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients
DeHoratius DM, Cowper SE. Editorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients. Seminars In Dialysis 2006, 19: 191-194. PMID: 16689966, DOI: 10.1111/j.1525-139x.2006.00152.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisSystemic fibrosisCases of NSFNephrogenic fibrosing dermopathyScleroderma-like diseaseRenal insufficiencyRenal patientsNSF patientsNephrology professionalsPatientsNephrology literatureSoft tissueTissue remodelingWound repairFibrosisSkinSpecific cellsComorbiditiesDermopathyInsufficiencySymptomsDiseaseNephrogenic systemic fibrosis: An update
Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: An update. Current Rheumatology Reports 2006, 8: 151-157. PMID: 16569375, DOI: 10.1007/s11926-006-0056-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThe role of circulating fibrocytes in fibrosis
Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Current Rheumatology Reports 2006, 8: 145-150. PMID: 16569374, DOI: 10.1007/s11926-006-0055-x.Peer-Reviewed Original ResearchConceptsPulmonary fibrosisFunctions of fibrocytesAreas of inflammationSerum amyloid PTissue repair responseFibrocyte traffickingInflammatory cytokinesPeripheral bloodMalignant potentialFibrotic lesionsStromal responseIL-1Skin lesionsPathologic fibrosisNew therapiesAmyloid PHypertrophic scarsTissue damageMatrix metalloproteinasesFibrosisRemodeling responseTumor invasionFibrocytesContractile myofibroblastsExperimental modelNephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis—Setting the Record Straight
Cowper SE, Bucala R, Leboit PE. Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis—Setting the Record Straight. Seminars In Arthritis And Rheumatism 2006, 35: 208-210. PMID: 16461067, DOI: 10.1016/j.semarthrit.2005.09.005.Commentaries, Editorials and Letters
2005
Nephrogenic Systemic Fibrosis: The Nosological and Conceptual Evolution of Nephrogenic Fibrosing Dermopathy
Cowper SE. Nephrogenic Systemic Fibrosis: The Nosological and Conceptual Evolution of Nephrogenic Fibrosing Dermopathy. American Journal Of Kidney Diseases 2005, 46: 763-765. PMID: 16183434, DOI: 10.1053/j.ajkd.2005.08.008.Commentaries, Editorials and LettersCase 35-2004: nephrogenic fibrosing dermopathy.
Cowper S, Bucala R, LeBoit P. Case 35-2004: nephrogenic fibrosing dermopathy. New England Journal Of Medicine 2005, 352: 1723-4; author reply 1723-4. PMID: 15846862.Peer-Reviewed Original Research
2003
Nephrogenic fibrosing dermopathy: the first 6 years
Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Current Opinion In Rheumatology 2003, 15: 785-790. PMID: 14569211, DOI: 10.1097/00002281-200311000-00017.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic fibrosing dermopathyRecent case reportsCase reportCutaneous fibrosing disorderYellow scleral plaquesDistinct clinical patternsDual immunohistochemical stainingAntiphospholipid antibodiesRenal insufficiencyClinical patternDual immunolabelingFibrosing disorderSystemic disordersClinical spectrumScleral plaquesDisease onsetEpidemiologic dataSpindle cellsImmunohistochemical stainingDisease triggersSkin conditionsDisease pathogenesisNormal skinRegistry projectDiagnostic tests